PF-3758309 was developed as an ATP-competitive inhibitor of PAK4. In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM). PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model. PF-3758309 is antiproliferative and induces apoptosis in an HCT116 tumor model.

FENIROFIBRATE, (-)- is a metabolite of fenofibrate, an antilipemic agent which reduces both cholesterol and triglycerides in the blood.

Phencarbamide is an anti-spasmodic and anticholinergic drug used during parturition. It has a specific antispasmodic action on the smooth muscle, both directly like papaverine and through the autonomic nervous system (atropine effect). It has also an analgesic effect of its own. Side-effects generally associated with the atropine group of drugs.

CBL0137 (also known as Curaxin CBL0137) is a metabolically stable curaxin and belongs to the class of small molecules with anti-cancer activity. CBL0137 is in Phase I clinical trials to treat hematological malignancies and solid tumors. CBL0137 binds to Facilitates Chromatin Transcription (FACT) and sequesters the FACT complex on chromatin, which inhibits its activity. This prevents transcription of certain genes involved in cancer-associated signaling pathways; it specifically inhibits the transcription of both NF-kappa β and heat shock transcription factor 1 (HSF1) and simultaneously activates p53. In addition, CBL0137 was investigated in vitro and in models mice for pancreatic ductal adenocarcinoma (PDA) and the obtained data suggested testing of CBL0137 efficacy in Phase II trial in PDA patients alone and in combination with gemcitabine.

Ritanserin (INN, USAN, BAN) is a serotonin receptor antagonist which was never marketed for clinical use but has been used in scientific research. In humans, ritanserin increases deep slow-wave sleep, improved liveliness in a variety of psychiatric disorders and facilitated participation in behaviour therapy. During clinical trials, unexpected observations indicated that ritanserin may be of value in treating obsessive-compulsive disorder, acute mania, negative symptoms of schizophrenia, drug addicts, etc. Clinical observations confirmed the efficacy of ritanserin in the chronic withdrawal phase after detoxification from ethanol. Ritanserin had been in phase III clinical trials by Janssen L.P. for the treatment of anxiety disorder and major depressive disorder. However, the clinical development of ritanserin was discontinued.

18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine, nicotine and sucrose. 18-MC is a α3β4 nicotinic antagonist and, in contrast to ibogaine, has no affinity at the α4β2 subtype nor at NMDA-channels nor at the serotonin transporter, and has significantly reduced affinity for sodium channels and for the σ receptor, but retains modest affinity for μ-opioid receptors where it acts as an antagonist, and κ-opioid receptors. The sites of action in the brain include the medial habenula, interpeduncular nucleus, dorsolateral tegmentum and basolateral amygdala. Unlike ibogaine and its principal metabolite noribogaine, 18-MC does not increase expression of glial cell line-derived neurotrophic factor (GDNF) in a dopaminergic–like cell line. 18-Methoxycoronaridine is a potent leishmanicide effect against Leishmania amazonensis, a causative agent of cutaneous and diffuse cutaneous leishmaniasis in the New World.

Propoxycarbazone-Sodium (also known as BAY MKH 6561) is asulfonylaminocarbonyltriazolinone derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as herbicide Propoxycarbazone inhibits acetolactate synthase (ALS), and has selectivity on spring, winter, and durum varieties. The spectrum of control includes several species of monocot and dicot weeds at the application rates of 30 to 45 g/ha. Bromus control is the primary target since existing herbicides have limited timing, selectivity, and use patterns which reduce usefulness. Propoxycarbazone applied postemergence between the 1- to 2-leaf stage and shoot elongation has provided economic control of the following Bromus species: B. tectorum, B. secalinus, B. mollis, B. rigidus, and B. japonicus. Side effects, and sometimes control, was also noted on Aegilops tauschii for which there is no selective control outside genetically altered wheat cultivars. Broadleaf control was obtained primarily on the mustard family, including species in the genera Sisymbrium, Brassica, Descurainia, Chorispora, Camelina, Capsella, and Thlaspi. Propoxycarbazone provides control for adequate weed spectrum, however, considerations of resistance management, difficult and diverse weed pressure, and extended growing seasons will sometimes necessitate the use of sequential herbicides or mix partners.